Brits have been tucking into curries for comfort during the pandemic. One survey showed orders for Indian takeaways doubled after Covid-19 hit. And the good news is that when chosen wisely, curry can be a hot tonic for your body. Experts say that spicy ingredients can help lower your risk of everything from cancer to… Read More »
Cholesterol-lowering statin drugs don’t just lower the risk of heart attacks. They may also help some cancer patients live longer. Researchers writing in the British Journal of Clinical Pharmacology tracked adherence to statins in more than 38,000 Australian women with newly diagnosed breast cancer, colorectal cancer or melanoma, three commonly diagnosed cancers. Average adherence to… Read More »
Aspirin has been called a wonder drug. And it’s easy to see why. It’s inexpensive, its side effects are well-known and generally minor. And since it was developed in the 1890s, it’s been shown to provide a number of potential benefits, such as relieving pain, bringing down a fever, and preventing heart attacks and strokes.… Read More »
Winship Cancer Institute of Emory University (Winship) and Emory investigators are testing whether an anticancer drug can reduce lung inflammation in hospitalized COVID-19 patients, possibly preventing the need for intubation and lowering mortality. The drug is called duvelisib, and it was FDA-approved in 2018 for the treatment of relapsed or refractory chronic lymphocytic leukemia or… Read More »
The 1st of October marked the beginning of Breast Cancer Awareness month and there’s loads of brands throwing their support behind raising awareness, helping out charities, as well as donating all important funding for research. Every 10 minutes in the UK, another woman is diagnosed with breast cancer. With this knowledge, it’s vital that we… Read More »
Compared with the spate of multibillion-dollar buyouts last year, biopharma M&A has been relatively quiet in 2020—until last week, when Gilead Sciences surprised the market with its $ 21 billion purchase of Immunomedics. Now, two sets of new cancer data from Immunomedics’ first-in-class antibody-drug conjugate Trodelvy offer a glimpse into why Gilead paid such big money… Read More »